Valsartan in early-stage hypertrophic cardiomyopathy: a randomized phase 2 trialCarolyn Y. Ho, Eugene Braunwald, Sharlene M. Day et al.|Nature Medicine|2021Cited by 132
Quality of Life and Exercise Capacity in Early Stage and Subclinical Hypertrophic Cardiomyopathy: A Secondary Analysis of the VANISH TrialCatherine G. Ireland, Carolyn Y. Ho, Danielle S. Burstein et al.|Circulation Heart Failure|2024Cited by 6
Phenotypic Spectrum of Subclinical Sarcomere-Related Hypertrophic Cardiomyopathy and Transition to Overt DiseaseConstantin‐Cristian Topriceanu, Carolyn Y. Ho, James Moon et al.|Circulation Genomic and Precision Medicine|2024Cited by 3
Proteomic Analysis of Valsartan for Attenuating Disease Evolution in Early Sarcomeric Hypertrophic Cardiomyopathy (VANISH) Clinical TrialConstantin‐Cristian Topriceanu, Carolyn Y. Ho, Steven D. Colan et al.|Circulation Heart Failure|2025Cited by 3
Abstract 12135: Quality of Life in Early-Stage Hypertrophic Cardiomyopathy: A Secondary Analysis of the VANISH TrialCatherine G. Ireland, Carolyn Y. Ho, Sharlene M. Day et al.|Circulation|2023Cited by 0